Fredrik Widman Sells 2,067 Shares of Intuitive Surgical (NASDAQ:ISRG) Stock

Intuitive Surgical, Inc. (NASDAQ:ISRG) VP Fredrik Widman sold 2,067 shares of the stock in a transaction dated Wednesday, November 5th. The stock was sold at an average price of $550.00, for a total value of $1,136,850.00. Following the sale, the vice president directly owned 473 shares in the company, valued at $260,150. This trade represents a 81.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Intuitive Surgical Stock Down 0.1%

ISRG traded down $0.77 during trading on Thursday, reaching $547.78. 1,494,452 shares of the company were exchanged, compared to its average volume of 2,118,475. The company’s 50-day moving average is $468.68 and its two-hundred day moving average is $499.90. The company has a market cap of $196.37 billion, a price-to-earnings ratio of 72.46, a P/E/G ratio of 4.94 and a beta of 1.62. Intuitive Surgical, Inc. has a 12-month low of $425.00 and a 12-month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings data on Tuesday, October 21st. The medical equipment provider reported $2.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.41. Intuitive Surgical had a return on equity of 15.08% and a net margin of 28.58%.The business had revenue of $2.51 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same quarter in the prior year, the firm posted $1.84 EPS. The firm’s quarterly revenue was up 22.9% on a year-over-year basis. Equities analysts forecast that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current year.

Analyst Ratings Changes

ISRG has been the topic of several recent analyst reports. Argus raised their price target on Intuitive Surgical from $600.00 to $630.00 in a report on Monday, October 27th. Piper Sandler raised their price target on Intuitive Surgical from $595.00 to $610.00 and gave the company an “overweight” rating in a report on Wednesday, October 22nd. Hsbc Global Res raised Intuitive Surgical to a “strong-buy” rating in a report on Thursday, October 23rd. Wall Street Zen upgraded Intuitive Surgical from a “hold” rating to a “buy” rating in a research report on Sunday, October 26th. Finally, Sanford C. Bernstein reiterated an “outperform” rating and set a $685.00 price objective on shares of Intuitive Surgical in a research report on Tuesday, October 21st. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Intuitive Surgical presently has a consensus rating of “Moderate Buy” and a consensus price target of $608.92.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of ISRG. Tobam lifted its stake in Intuitive Surgical by 666.7% in the 2nd quarter. Tobam now owns 46 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 40 shares in the last quarter. Kilter Group LLC purchased a new position in Intuitive Surgical in the 2nd quarter worth approximately $27,000. Greykasell Wealth Strategies Inc. purchased a new position in Intuitive Surgical in the 3rd quarter worth approximately $27,000. TD Capital Management LLC raised its position in shares of Intuitive Surgical by 300.0% during the 1st quarter. TD Capital Management LLC now owns 60 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 45 shares during the period. Finally, 1248 Management LLC purchased a new stake in shares of Intuitive Surgical during the 1st quarter valued at approximately $30,000. 83.64% of the stock is owned by hedge funds and other institutional investors.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.